{"id":54514,"date":"2023-03-06T14:03:19","date_gmt":"2023-03-06T13:03:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2023-03-06T14:03:19","modified_gmt":"2023-03-06T13:03:19","slug":"urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (\u201cRSUs\u201d) to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and March 6, 2023. These new team members will support the ongoing commercial launch of Jelmyto\u00ae (mitomycin) for pyelocalyceal solution, UroGen\u2019s first approved product, and the continued development of the Company\u2019s pipeline.\n<\/p>\n

<\/a><\/p>\n

\nUp to 11,700 shares of UroGen\u2019s common stock are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee\u2019s continued service relationship with UroGen.\n<\/p>\n

\nThe RSUs are subject to the terms and conditions of UroGen\u2019s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSU grants were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).\n<\/p>\n

\nAbout UroGen Pharma Ltd.<\/b>\n<\/p>\n

\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGelTM<\/sup> reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen\u2019s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen\u2019s first commercial product Jelmyto\u00ae (mitomycin) for pyelocaliceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. Visit www.urogen.com<\/a> to learn more or follow us on Twitter, @UroGenPharma.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR CONTACT:
\n
Vincent Perrone
\n
vincent.perrone@urogen.com<\/a>
(609) 460-3588\n<\/p>\n

\nMEDIA CONTACT:
\n
Cindy Romano
\n
Cindy.romano@urogen.com<\/a>
(609) 460-3583\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (\u201cRSUs\u201d) to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54514","6":"format-standard","7":"category-industry"},"yoast_head":"\nUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (\u201cRSUs\u201d) to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-06T13:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-03-06T13:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":353,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005090\\\/en\\\/1729438\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005090\\\/en\\\/1729438\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"datePublished\":\"2023-03-06T13:03:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005090\\\/en\\\/1729438\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005090\\\/en\\\/1729438\\\/21\\\/UroGen_logo2_%28R%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","og_description":"PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (\u201cRSUs\u201d) to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-06T13:03:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-03-06T13:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"wordCount":353,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/","name":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg","datePublished":"2023-03-06T13:03:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230306005090\/en\/1729438\/21\/UroGen_logo2_%28R%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54514"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54514\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}